anti-BCMA/CD3 bispecific antibody

DRUG4 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China

Conditions

Multiple MyelomaMultiple Myeloma (MM)Systemic Light Chain Amyloidosis

Phase 2

BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

RecruitingNCT07151690

Institute of Hematology & Blood Diseases Hospital, ChinaSystemic Light Chain Amyloidosis

Start: 2025-09-04End: 2027-12-01Target: 21Updated: 2026-07-23

MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma

RecruitingNCT07409454

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma

Start: 2026-07-07End: 2028-12-31Target: 20Updated: 2026-08-07

CM336-SOC for Dynamically High-Risk Multiple Myeloma Study

Not yet recruitingNCT07648459

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma

Start: 2026-10-01End: 2028-07-30Target: 46Updated: 2026-08-26

Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma

Not yet recruitingNCT07789522

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma (MM)

Start: 2026-10-01End: 2028-10-30Target: 15Updated: 2026-08-27